Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLiabilities from Discontinued OperationsLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ligand Pharmaceuticals (LGND) Cash & Equivalents: 2009-2024

Historic Cash & Equivalents for Ligand Pharmaceuticals (LGND) over the last 16 years, with Dec 2024 value amounting to $72.3 million.

  • Ligand Pharmaceuticals' Cash & Equivalents rose 119.08% to $139.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $139.4 million, marking a year-over-year increase of 119.08%. This contributed to the annual value of $72.3 million for FY2024, which is 215.01% up from last year.
  • Latest data reveals that Ligand Pharmaceuticals reported Cash & Equivalents of $72.3 million as of FY2024, which was up 215.01% from $23.0 million recorded in FY2023.
  • In the past 5 years, Ligand Pharmaceuticals' Cash & Equivalents ranged from a high of $72.3 million in FY2024 and a low of $19.5 million during FY2021.
  • Its 3-year average for Cash & Equivalents is $46.8 million, with a median of $45.0 million in 2022.
  • Its Cash & Equivalents has fluctuated over the past 5 years, first plummeted by 59.00% in 2021, then spiked by 215.01% in 2024.
  • Ligand Pharmaceuticals' Cash & Equivalents (Yearly) stood at $47.6 million in 2020, then slumped by 59.00% to $19.5 million in 2021, then surged by 130.54% to $45.0 million in 2022, then slumped by 49.00% to $23.0 million in 2023, then soared by 215.01% to $72.3 million in 2024.